Abstracts

754 – Comorbidities Among Medicaid Enrollees With Chronic Hepatitis C, 2016-2020

Background To achieve hepatitis C elimination in the United States (US), understanding comorbidities among people living with chronic hepatitis C is crucial to inform prevention and treatment approaches. We aimed to quantify and characterize the prevalence of HIV, sexually transmitted infections (STIs), mental health disorders, substance use disorders, and drug overdose among Medicaid enrollees diagnosed…

710 – Preclinical Evaluation of an Ultra-Long-Acting Tenofovir Prodrug Nanosuspension

Background Effective treatment of hepatitis B (CHBV) infection requires adherence to long-term daily antiviral therapies. These include oral tenofovir (TFV) prodrugs [TFV disoproxil-/TFV alafenamide-fumarate – TDF/TAF] or entecavir. Treatment cessation leads to HBV reactivation and disease progression. This underscores the need for long-acting formulations to improve treatment outcomes. Considering these needs, we developed a scalable amino…

769 – HBsAg Seroclearance in HBV-Coinfected People With HIV in the Era of Tenofovir-Containing Therapy

Background Long-term tenofovir-containing antiretroviral therapy (ART) achieves durable suppression of HIV and HBV, but its effect on functional cure of HBV infeciton in people with HIV (PWH) remains unclear. We aimed to determine the incidence of and factors associated with hepatitis B surface antigen (HBsAg) loss after treatment with tenofovir-containing ART in HBV-coinfected PWH. Methods…

775 – HBV Seroconversion in People With HIV: Relevance of Clinical History and Viral Markers Monitoring

Background Treatment including tenofovir disoproxil (TDF) or alafenamide (TAF) is the standard of care in people living with HIV/HBV infection. Serum HBV-RNA is an emerging biomarker reflecting the activity of intrahepatic HBV reservoir. The aim of the study was to describe HBV seroconversion (HBV-S) rate in HIV/HBV subjects on HBV-active therapy and to analyse markers…

784 – In Vitro and In Vivo Immunogenicity of a Dendritic Cell-Based Vaccine Targeting HBV Epitopes

Background Persistent chronic HBV infection is associated with impaired functional T-cell specific responses and a lack of memory T-cells against core (C), polymerase (P), and envelope proteins (S). Therapeutic vaccination is aimed to relieve exhausted T-cells and to stimulate recall memory T-cells. We have developed an antigen-presenting cell (APC)-targeting approach allowing the delivery of specific…

760 – Distinct Metabolic Perturbations Link Liver Steatosis and Incident CVD in Lean but Not Obese PLHIV

Background Metabolic dysfunction-associated steatotic liver disease (MASLD) is a key risk factor for cardiovascular disease (CVD), potentially driven by shared metabolic mechanisms. However, the metabolic perturbations linking MASLD and CVD remains unexplored in people living with HIV (PLHIV). Methods We investigated subjects from the longitudinal multicenter 2000HIV study (NCT03994835), which included 1895 virally suppressed PLHIV…

778 – HeCaPred: An AI-Based Algorithm for HCC Prediction in Patients With HCV Chronic Infection After SVR

Background Achieving sustained virological response (SVR) reduces the risk of liver decompensation and hepatocellular carcinoma (HCC) in patients with chronic hepatitis C virus (HCV) infection and advanced liver disease. Life-long HCC surveillance is recommended after HCV cure, but its cost-effectiveness is uncertain, especially in the context of HIV co-infection, where data remain scarce. Methods Multicenter…

750 – High HCV Reinfection Rates May Mask “True” Sustained Virologic Response in People Who Inject Drugs

Background Eliminating HCV requires curing people and ensuring they remain free of re-infection. People who inject drugs (PWID) are particularly vulnerable to re-infection, but few re-infection estimates are available from resource-limited settings. We evaluate HCV re-infection rates among PWID treated in community-based centers in 7 Indian cities.  Methods From 2021-2022, 3000 PWID ≥18 years with…